Company / R&D Expense
Minerva Neurosciences, Inc. R&D Expense History
FY2017-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$11.9M
FY2024
5-year range
$11.9M / $58.1M
FY2020-FY2024
Trend
-18.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 8 years, ranging from $12M in FY2024 to $58M in FY2020.
Based on SEC 10-K filings.
$12M in FY2024 with a 5-year CAGR of -19.4%.
Declined from $32M to $12M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -18.6%
- 5-Year CAGR
- -19.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -19.4%, indicating a declining trend.
- In FY2024, r&d expense decreased 18.8% year-over-year.
- Peak r&d expense was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -10.64 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $11.9M | -18.8% |
| FY2023 | $14.6M | -54.3% |
| FY2022 | $32.0M | +45.4% |
| FY2021 | $22.0M | -62.1% |
| FY2020 | $58.1M | +66.6% |
| FY2019 | $34.9M | +15.3% |
| FY2018 | $30.3M | +63.3% |
| FY2017 | $18.5M | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026